CDK4 and breast cancer: The inclusion of CDK4/6 inhibitors in combination with endocrine therapy in international treatment guidelines, both as initial therapy and after disease progression following ET, represents the most relevant advance in the management of HR-positive, HER2-negative advanced, or metastatic BC over the past decade [44,45,46].